REG - IQ-AI Limited - Agreement with St. Jude Children’s Hospital

IQ-AIAnnouncement

11/11/2021 08:55

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211111:nRSK0858Sa&default-theme=true

RNS Number : 0858S  IQ-AI Limited  11 November 2021

11 November 2021

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Imaging Biometrics and St. Jude Children's Hospital Enter Agreement

IB Zero G™ Technology May Benefit Imaging in Paediatric Patients

Milwaukee - 11 November 2021:  IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a
developer of medical image processing platforms that have led to effective
therapeutic strategies for brain tumor and other patients, and St. Jude
Children's Hospital (Memphis, TN), have entered into a Data Use Agreement. The
Agreement is a specific type of agreement required under the Health Insurance
Portability and Accountability Act (HIPPA) Privacy Rule. It will provide
Imaging Biometrics (IB) access to paediatric imaging datasets for use in the
development of its patented, artificial intelligence (AI) technology, IB Zero
G.

St. Jude Children's Hospital is the only National Cancer Institute
(NCI)-designated Comprehensive Care Centre devoted solely to children. It has
received the NCI's highest ranking of "exceptional" and has treated children
from all 50 US states and from around the world.

Through this Agreement, IB will have access to a wide array of magnetic
resonance (MR) datasets acquired in children of all ages. Diverse and
accurately labelled (annotated) data are critical for developing and refining
AI models. High quality data enables AI models to accurately analyze new,
incoming, real-world image datasets. IB Zero G will use this data to generate
synthetic contrast-enhanced images for paediatric neuro examinations.

Gadolinium Based Contrast Agents (GBCAs) have been used clinically in MRI
examinations for decades and provide invaluable diagnostic information. In
2006, safety concerns were raised for GBCA use in patients due to the
causative effect in a condition called nephrogenic systemic fibrosis (NSF).
Since then, the awareness and understanding about GBCA use has escalated
worldwide. More recently, it was found that repeated exposure of GBCAs result
in its retention throughout the body. While the long-term adverse side effects
are not known, the detrimental concerns for critical periods of life and
especially on rapidly developing bone or brain, remain.

"This Agreement will accelerate the development and commercialization of IB
Zero G," said Trevor Brown CEO of IQAI "Avoiding the use of GBCAs while
preserving the diagnostic quality on paediatric images will help clinicians
address concerns relating to GBCA retention and ultimately provide better
care," he added.

IQAI is preparing to submit an FDA 510(k) application for IB Zero G late Q1
2022.

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

-ENDS-

 

For further information, please contact:

 IQ-AI Limited

 Trevor Brown/Brett Skelly/Vinod Kaushal

 Tel: 020 7469 0930

 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

About Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON: IQAI) (OTCQB:
IQAIF), develops and provides visualisation and analytical solutions that
enable clinicians to better diagnose and treat disease with greater
confidence. Through close collaboration with top researchers and clinicians,
sophisticated advancements are translated into platform-independent and
automated software plug-ins which can extend the base functionality of
workstations, imaging systems, PACS, or medical viewers. By design, IB's
advanced visualisation software seamlessly integrates into routine workflows.
For more information about Imaging Biometrics, visit the company's website at
www.imagingbiometrics.com (http://www.imagingbiometrics.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGIBDBCSBDGBB